These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 19766715

  • 1. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy.
    Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arnér ES.
    Free Radic Biol Med; 2009 Dec 01; 47(11):1661-71. PubMed ID: 19766715
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
    Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS.
    Lung Cancer; 2009 Dec 01; 66(3):298-304. PubMed ID: 19324449
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinoma.
    Iwasawa S, Yamano Y, Takiguchi Y, Tanzawa H, Tatsumi K, Uzawa K.
    Oncol Rep; 2011 Mar 01; 25(3):637-44. PubMed ID: 21206984
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, Gonzalez-Barón M, Perona R.
    Oncogene; 2006 Jun 01; 25(23):3335-45. PubMed ID: 16462770
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
    Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A.
    Cancer Res; 2006 Apr 15; 66(8):4410-8. PubMed ID: 16618767
    [Abstract] [Full Text] [Related]

  • 18. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
    Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupé P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E, Kroemer G.
    Cancer Res; 2010 Mar 01; 70(5):1793-803. PubMed ID: 20145152
    [Abstract] [Full Text] [Related]

  • 19. Thioredoxin reductase 1 upregulates MCP-1 release in human endothelial cells.
    Liu ZB, Shen X.
    Biochem Biophys Res Commun; 2009 Sep 04; 386(4):703-8. PubMed ID: 19555664
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
    Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP.
    Free Radic Biol Med; 2007 Mar 15; 42(6):872-81. PubMed ID: 17320769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.